文献速递临床试验与 GCP

挥发性麻醉与全凭静脉麻醉对心脏手术后慢性术后疼痛的影响:基于IMMPACT标准的前瞻性随机对照试验研究方案

Influence of volatile anesthesia versus total intravenous anesthesia on chronic postsurgical pain after cardiac surgery using the Initiative on Methods, Measurement, and Pain Assessment in Clinical Trials criteria: study protocol for a prospective randomized controlled trial.
PubMed 文献 · Trials · 2019-11-27

本研究为前瞻性随机对照试验,计划纳入500例成人心脏手术患者,随机分为挥发性麻醉组(七氟烷或地氟烷)与丙泊酚全凭静脉麻醉(TIVA)组,采用IMMPACT推荐标准评估术后3个月、6个月和1年的慢性术后疼痛(CPSP)发生率,以比较两种麻醉方案对CPSP的预防效果。

要点

  • 心脏手术后CPSP影响睡眠、情绪和生活质量,丙泊酚相比挥发性麻醉药可能改善术后镇痛。
  • 研究纳入500例成人心脏手术患者,随机分为挥发性麻醉组与丙泊酚TIVA组。
  • 主要结局为术后3个月、6个月和1年CPSP发生率,CPSP定义为胸骨或胸部疼痛且NRS>0或满足全部6条IMMPACT标准。

核心结论

  • 据作者所知,这是首项采用经验证的疼痛工具并遵循IMMPACT推荐、比较挥发性麻醉与丙泊酚TIVA对心脏手术后CPSP预防效果的前瞻性随机对照试验。
  • 该研究将为两种麻醉方案中哪一种更有利于预防心脏手术后CPSP提供重要信息。

研究设计与样本

  • 前瞻性随机对照试验,计划纳入500例接受心脏手术的成人患者,随机分配至挥发性麻醉组或TIVA组。
  • 挥发性麻醉组在手术期间接受七氟烷或地氟烷全身麻醉;TIVA组接受丙泊酚静脉麻醉药且术中不使用挥发性麻醉药。
  • 主要结局为术后3个月、6个月和1年时CPSP的发生频率,CPSP指胸骨或胸部疼痛。

主要发现

  • CPSP定义为满足以下任一条件:(1)数字评定量表(NRS)>0;(2)满足全部6条IMMPACT的CPSP标准。
  • IMMPACT标准为经验证的疼痛评估工具。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Many patients develop chronic postsurgical pain (CPSP) after cardiac surgery, which interferes with their sleep, mood, and quality of life. Studies have suggested that propofol improves postoperative analgesia compared with volatile anesthetics, but its preventive effect on CPSP following cardiac surgery is still unknown. This study compares the incidence of CPSP following cardiac surgery for those receiving volatile anesthesia and those receiving propofol-based total intravenous anesthesia (TIVA) using criteria recommended by the Initiative on Methods, Measurement, and Pain Assessment in Clinical Trials (IMMPACT). METHODS/DESIGN: This is a prospective randomized controlled trial. In total, 500 adults undergoing cardiac surgery will be randomly allocated to the volatile or the TIVA group. The volatile group will receive sevoflurane or desflurane during surgery as general anesthesia. The TIVA group will receive propofol-based intravenous agents and no volatile agents during surgery. The primary outcomes will be the frequency of CPSP at 3 months, 6 months, and 1 year after surgery. In this case, CPSP is sternal or thoracic pain. It is defined as either (1) numerical rating scale (NRS) > 0 or (2) meeting all six IMMPACT criteria for CPSP. The IMMPACT criteria are validated pain instruments. DISCUSSION: To our knowledge, this is the first prospective randomized controlled trial to investigate the prevention of CPSP following cardiac surgery for patients receiving volatile anesthesia compared to those receiving propofol-based TIVA using validated pain instruments in accordance with the IMMPACT recommendations. This study will provide important information on which of these two anesthetic regimens is better for preventing CPSP after cardiac surgery. TRIAL REGISTRATION: Chictr.org.cn, ChiCTR1900020747. Registered on 16 January 2019.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Yu H, Zheng JQ, Hua YS, et al. Influence of volatile anesthesia versus total intravenous anesthesia on chronic postsurgical pain after cardiac surgery using the Initiative on Methods, Measurement, and Pain Assessment in Clinical Trials criteria: study protocol for a prospective randomized controlled trial. Trials. 2019. PMID: 31775854. doi:10.1186/s13063-019-3742-4

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。